What topics does this cannabis study cover?

This study covers research on: Epilepsy, CBD, Neuroprotection.

Where was this research published?

Published in Epilepsia open on June 11, 2026.

CBD shows promise in breakthrough Lennox-Gastaut syndrome model

Q: What did this research study find?

Lennox-Gastaut syndrome (*LGS*) is a rare and **difficult-to-treat form of childhood epilepsy** that has long frustrated researchers and patients alike. This study describes the development of a **new mouse model** using genetically modified mice with a *Gabrb3* mutation that accurately reproduces t

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox-Gastaut syndrome.

Epilepsia open • June 11, 2026 • Moderately Relevant

🤖

AI Summary

Lennox-Gastaut syndrome (LGS) is a rare and difficult-to-treat form of childhood epilepsy that has long frustrated researchers and patients alike. This study describes the development of a new mouse model using genetically modified mice with a Gabrb3 mutation that accurately reproduces the two hallmark seizure types seen in LGS patients: atypical absence seizures (brief periods of unresponsiveness) and infantile spasms (sudden jerking movements in infants). Researchers used video-EEG monitoring to document seizure activity and test how different medications affected the mice.

The groundbreaking finding was that cannabidiol (CBD) significantly reduced both seizure types in the mouse model. Adult mice treated with CBD showed reduced seizure incidence and duration, while young mice treated with CBD displayed substantially fewer infantile spasms compared to untreated controls. These results matched or exceeded the effectiveness of established antiseizure medications like ethosuximide and vigabatrin, suggesting that CBD may offer a promising therapeutic option for LGS patients. The mouse model itself proved valuable, as it demonstrates sensitivity to known antiseizure treatments, establishing its validity for future drug discovery.

This research is particularly significant because LGS remains drug-resistant in about 30-40% of patients, leaving families desperate for new treatment options. By showing that CBD works effectively in a genetically accurate disease model, this study provides strong preclinical evidence supporting further clinical investigation of cannabinoid-based therapies for severe developmental epilepsies. The researchers emphasize that this mouse model can now serve as a translational platform for evaluating novel cannabinoid therapeutics, potentially accelerating the development of life-changing treatments for children with devastating seizure disorders.

📄 Original Abstract

Lennox-Gastaut syndrome (LGS) is a drug-resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome-relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock-in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and assessing their sensitivity to antiseizure agents. Video-EEG recordings of adult (10-week-old) KI and wild-type (WT) littermates were scored for atypical absence seizures, and the acute effects of ethosuximide (200 mg/kg), ulixacaltamide (60 mg/kg), and cannabidiol (CBD, 100 mg/kg) on seizure incidence and duration were evaluated using a within-subjects, crossover design. Video recordings of postnatal day 16 (P16) KI and WT littermates were scored for epileptic spasms, and the effects of once-daily dosing with vigabatrin (100 mg/kg) and CBD (100 mg/kg) from P13 to P15 were evaluated against vehicle. Adult KI but not WT mice exhibited spontaneous atypical absence seizures. CBD, ethosuximide, and ulixacaltamide reduced seizure incidence and duration. Epileptic spasms were more frequent in KI than in WT mice at P16. CBD and vigabatrin significantly reduced spasm frequency compared to the vehicle. Gabrb3+/D120N mice display robust atypical absence seizures and neonatal spasms that respond to antiseizure agents, supporting the predictive validity of this model as a preclinical platform for LGS drug discovery. CBD produced reductions in both atypical absence seizures and infantile spasms, suggesting that this model may be utilized as a translational tool for evaluating novel cannabinoid therapeutics for DEEs. Lennox-Gastaut syndrome (LGS) is a rare type of epilepsy that's hard to treat and poses a challenge for developing new drugs. Finding suitable animal models that accurately represent LGS is crucial. This article describes the development of a mouse model of LGS with a genetic mutation that increases seizures and epileptic spasms. We tested how different antiseizure drugs affect the mice. CBD, ethosuximide, and ulixacaltamide reduced seizure incidence and duration. CBD and vigabatrin also reduced spasm frequency in young mice. These promising results suggest the mouse model could be a valuable tool for drug discovery in LGS.

Paper Type

📄 Research

Publication

Journal: Epilepsia open
Published: June 11, 2026
PMID: 42274296
DOI: 10.1002/epi4.70289

Authors (6)

Thomas Harman Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Laura A Sharman Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Ka Lai Yip Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Miguel Bedoya-Pérez Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.
Vaishali Janve Department of Anesthesiology, Vanderbilt University, Nashville, Tennessee, USA.
+1 more authors